Search

Your search keyword '"Domanski, Olivia"' showing total 43 results
Start Over Author "Domanski, Olivia"
43 results on '"Domanski, Olivia"'

3. Management and outcomes of pregnant women with cardiovascular diseases in a cardio-obstetric team

Author

Richardson, Marjorie, Bonnet, Jean Philippe, Coulon, Capucine, Domanski, Olivia, Constans, Benjamin, Estevez, Max Gonzalez, Gautier, Sophie, Marsili, Luisa, Hamoud, Yasmine Ould, Coisne, Augustin, Ridon, Hélène, Polge, Anne-Sophie, Mouton, Stéphanie, Haddad, Yasmine, Juthier, Francis, Moussa, Mouhamed, Vehier, Claire Mounier, Lemesle, Gilles, Schurtz, Guillaume, Garabedian, Charles, Jourdain, Mercedes, Ninni, Sandro, Brigadeau, François, Montaigne, David, Lamblin, Nicolas, and Ghesquiere, Louise

Published
2024
Full Text
View/download PDF

12. Health‐Related Quality of Life and Its Association With Outcomes in Adults With Congenital Heart Disease and Heart Failure: Insight From FRESH‐ACHD Registry

Author

Ly, Reaksmei, primary, Karsenty, Clément, additional, Amedro, Pascal, additional, Cohen, Sarah, additional, Domanski, Olivia, additional, Godart, Francois, additional, Radojevic, Jelena, additional, Vaksmann, Guy, additional, Naccache, Nicole, additional, Boubrit, Anissa, additional, Bataille, Vincent, additional, Hascoet, Sébastien, additional, and Ladouceur, Magalie, additional

Published
2023
Full Text
View/download PDF

15. Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy

Author

Le Duc, Kévin, Gilliot, Sixtine, Baudelet, Jean Benoit, Mur, Sébastien, Boukhris, Mohamed Riadh, Domanski, Olivia, Odou, Pascal, and Storme, Laurent

Subjects
ductus arteriosus, Pharmacology, PPHN (persistent pulmonary hypertension of the newborn), cardiovascular system, Case Report, Pharmacology (medical), pregnancy, neonate, NSAID (non-steroidal anti-inflammatory drug), NICU (neonatal intensive care unit)
Abstract

Background: The use of non-steroidal anti-inflammatory drugs (NSAIDs) during the third trimester of pregnancy can cause premature constriction of the ductus arteriosus. This report describes a case of in utero narrowing of the ductus arteriosus (DA) diagnosed postnatally in a baby with Persistent Pulmonary Hypertension of the Newborn (PPHN), after maternal use of Diclofenac-Epolamine 140 mg patch during the second and third trimester. Case Presentation: A fetal ultrasounds revealed an enlarged hypertrophic right ventricle at 32 weeks of gestation. Detailed questioning of the mother highlighted that topical Diclofenac (FLECTOR®) had been used at 26 and at 31 weeks of gestation. An echocardiography performed 8 h postnatally showed supra-systemic pulmonary hypertension, a restrictive ductus arteriosus and a dilated right ventricle. The newborn was treated by inhaled nitric oxide and oral Sildenafil and was discharged from hospital on day 24. He had a complete normalization of his pulmonary vascular resistance on day 48. Conclusion: This case illustrates the potential fetal and neonatal complications associated with maternal topical Diclofenac medication during pregnancy resulting in antenatal closure of the DA.

Published
2021
Full Text
View/download PDF

16. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib

Author

Morin, Gabriel, primary, Degrugillier-Chopinet, Caroline, additional, Vincent, Marie, additional, Fraissenon, Antoine, additional, Aubert, Hélène, additional, Chapelle, Célia, additional, Hoguin, Clément, additional, Dubos, François, additional, Catteau, Benoit, additional, Petit, Florence, additional, Mezel, Aurélie, additional, Domanski, Olivia, additional, Herbreteau, Guillaume, additional, Alesandrini, Marie, additional, Boddaert, Nathalie, additional, Boutry, Nathalie, additional, Broissand, Christine, additional, Han, Tianxiang Kevin, additional, Branle, Fabrice, additional, Sarnacki, Sabine, additional, Blanc, Thomas, additional, Guibaud, Laurent, additional, and Canaud, Guillaume, additional

Published
2022
Full Text
View/download PDF

18. Prognostic values of exercise echocardiography and cardiopulmonary exercise testing in patients with primary mitral regurgitation

Author

Coisne, Augustin, primary, Aghezzaf, Samy, additional, Galli, Elena, additional, Mouton, Stéphanie, additional, Richardson, Marjorie, additional, Dubois, Denis, additional, Delsart, Pascal, additional, Domanski, Olivia, additional, Bauters, Christophe, additional, Charton, Marion, additional, L'Official, Guillaume, additional, Modine, Thomas, additional, Vincentelli, André, additional, Juthier, Francis, additional, Lancellotti, Patrizio, additional, Donal, Erwan, additional, and Montaigne, David, additional

Published
2021
Full Text
View/download PDF

20. Prognostic values of exercise echocardiography and cardiopulmonary exercise testing in patients with primary mitral regurgitation.

Author

Coisne, Augustin, Aghezzaf, Samy, Galli, Elena, Mouton, Stéphanie, Richardson, Marjorie, Dubois, Denis, Delsart, Pascal, Domanski, Olivia, Bauters, Christophe, Charton, Marion, L'Official, Guillaume, Modine, Thomas, Vincentelli, André, Juthier, Francis, Lancellotti, Patrizio, Donal, Erwan, and Montaigne, David

Subjects
MITRAL valve insufficiency, EXERCISE tests, ECHOCARDIOGRAPHY, BLOOD pressure, AEROBIC capacity, VENTRICULAR ejection fraction, CONFIDENCE intervals, CARDIOPULMONARY system, PULMONARY hypertension, PULMONARY artery, DECISION making in clinical medicine, LONGITUDINAL method
Abstract

Aims To compare the clinical significance of exercise echocardiography (ExE) and cardiopulmonary exercise testing (CPX) in patients with ≥moderate primary mitral regurgitation (MR) and discrepancy between symptoms and MR severity. Methods and results Patients consulting for ≥moderate discordant primary MR prospectively underwent low (25 W) ExE, peak ExE, and CPX within 2 months in Lille and Rennes University Hospital. Patients with Class I recommendation for surgical MR correction were excluded. Changes in MR severity, systolic pulmonary artery pressure (SPAP), left ventricular ejection fraction (LVEF), and tricuspid annular plane systolic excursion were evaluated during ExE. Patients were followed for major events (ME): cardiovascular death, acute heart failure, or mitral valve surgery. Among 128 patients included, 22 presented mild-to-moderate, 61 moderate-to-severe, and 45 severe MR. Unlike MR variation, SPAP and LVEF were successfully assessed during ExE in most patients. Forty-one patients (32%) displayed reduced aerobic capacity (peak VO2 < 80% of predicted value) with cardiac limitation in 28 (68%) and muscular or respiratory limitation in the 13 others (32%). ME occurred in 61 patients (47.7%) during a mean follow-up of 27 ± 21 months. Twenty-five Watts SPAP [hazard ratio (HR) (95% confidence interval, CI) = 1.03 (1.01–1.06), P = 0.003] and reduced aerobic capacity [HR (95% CI) = 1.74 (1.03–2.95), P = 0.04] were independently predictive of ME, even after adjustment for MR severity. The cut-off of 55 mmHg for 25 W SPAP showed the best accuracy to predict ME (area under the curve = 0.60, P = 0.05). Conclusion In patients with ≥moderate primary MR and discordant symptoms, 25 W exercise pulmonary hypertension, defined as an SPAP ≥55 mmHg, and poor aerobic capacity during CPX are independently associated with adverse events. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Prognostic value of aerobic capacity and exercise oxygen pulse in postaortic dissection patients

Author

Delsart, Pascal, primary, Delahaye, Camille, additional, Devos, Patrick, additional, Domanski, Olivia, additional, Azzaoui, Richard, additional, Sobocinski, Jonathan, additional, Juthier, Francis, additional, Vincentelli, Andre, additional, Rousse, Natacha, additional, Mugnier, Agnes, additional, Soquet, Jerome, additional, Loobuyck, Valentin, additional, Koussa, Mohamed, additional, Modine, Thomas, additional, Jegou, Bruno, additional, Bical, Antoine, additional, Hysi, Ilir, additional, Fabre, Olivier, additional, Pontana, François, additional, Matran, Regis, additional, Mounier‐Vehier, Claire, additional, and Montaigne, David, additional

Published
2020
Full Text
View/download PDF

34. An original cause of pulmonary hypertension

Author

Domanski, Olivia, primary, Algeri, Emanuela, additional, Fertin, Marie, additional, Petit, Gregory, additional, Lamblin, Nicolas, additional, Rémy-Jardin, Martine, additional, and de Groote, Pascal, additional

Published
2015
Full Text
View/download PDF

41. An unexpected rise in cardiac troponin I in a patient with multiple myeloma.

Author

Domanski, Olivia, Maréchaux, Sylvestre, Forzy, Gerard, and Lemahieu, Jean-Michel

Subjects
CHEST pain, FATIGUE (Physiology), MULTIPLE myeloma, TROPONIN
Abstract

The article describes the case of a 62-year-old patient who experienced fatigue and chest discomfort. Particular focus is given to the results of electrocardiography and blood tests conducted on the patient who had a history of multiple myeloma and systemic hypertension. It notes that a rise in cardiac troponin I (cTnI) may occur in pulmonary embolism, sepsis or stress-induced cardiomyopathy. The increase in serum cTnI concentration is not always associated with myocardial injury.

Published
2012
Full Text
View/download PDF

42. Prognostic values of exercise echocardiography and cardiopulmonary exercise testing in patients with primary mitral regurgitation.

Author

Coisne A, Aghezzaf S, Galli E, Mouton S, Richardson M, Dubois D, Delsart P, Domanski O, Bauters C, Charton M, L'Official G, Modine T, Vincentelli A, Juthier F, Lancellotti P, Donal E, and Montaigne D

Subjects
Humans, Exercise Test, Prognosis, Stroke Volume, Ventricular Function, Left, Echocardiography, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency surgery
Abstract

Aims: To compare the clinical significance of exercise echocardiography (ExE) and cardiopulmonary exercise testing (CPX) in patients with ≥moderate primary mitral regurgitation (MR) and discrepancy between symptoms and MR severity., Methods and Results: Patients consulting for ≥moderate discordant primary MR prospectively underwent low (25 W) ExE, peak ExE, and CPX within 2 months in Lille and Rennes University Hospital. Patients with Class I recommendation for surgical MR correction were excluded. Changes in MR severity, systolic pulmonary artery pressure (SPAP), left ventricular ejection fraction (LVEF), and tricuspid annular plane systolic excursion were evaluated during ExE. Patients were followed for major events (ME): cardiovascular death, acute heart failure, or mitral valve surgery. Among 128 patients included, 22 presented mild-to-moderate, 61 moderate-to-severe, and 45 severe MR. Unlike MR variation, SPAP and LVEF were successfully assessed during ExE in most patients. Forty-one patients (32%) displayed reduced aerobic capacity (peak VO2 &lt; 80% of predicted value) with cardiac limitation in 28 (68%) and muscular or respiratory limitation in the 13 others (32%). ME occurred in 61 patients (47.7%) during a mean follow-up of 27 ± 21 months. Twenty-five Watts SPAP [hazard ratio (HR) (95% confidence interval, CI) = 1.03 (1.01-1.06), P = 0.003] and reduced aerobic capacity [HR (95% CI) = 1.74 (1.03-2.95), P = 0.04] were independently predictive of ME, even after adjustment for MR severity. The cut-off of 55 mmHg for 25 W SPAP showed the best accuracy to predict ME (area under the curve = 0.60, P = 0.05)., Conclusion: In patients with ≥moderate primary MR and discordant symptoms, 25 W exercise pulmonary hypertension, defined as an SPAP ≥55 mmHg, and poor aerobic capacity during CPX are independently associated with adverse events., Competing Interests: Conflict of interest: none declared., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

43. [Pulmonary revalvulation and rhythmologenic risks in patients with repaired tetralogy of Fallot].

Author

Pilato R, Lacroix D, Domanski O, and Godart F

Subjects
Age Factors, Cardiac Catheterization, Catheter Ablation, Cause of Death, Cryosurgery, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Humans, Postoperative Complications physiopathology, Risk Factors, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular prevention & control, Tetralogy of Fallot physiopathology, Death, Sudden, Cardiac etiology, Postoperative Complications etiology, Tachycardia, Ventricular etiology, Tetralogy of Fallot surgery
Abstract

Tetralogy of Fallot is a frequent congenital heart disease that has been repaired since the mid-1950s. The follow-up after repair is good despite a persistent risk of sudden death. The risk factors in long-term follow-up are advanced age at repair, hemodynamic status of the right ventricle, QRS duration≥180ms, left ventricular dysfunction, and existence of sustained or not ventricular tachycardia. In the presence of significant pulmonary regurgitation, it is necessary to perform revalvulation either by classic surgery or cardiac catheterization. To correct the risk of ventricular arrhythmia, some have proposed radiofrequency ablation of critical isthmus, or cryo-application during surgery. However, the use of implantable cardioverter defibrillator is another therapeutic option that is more and more employed as secondary or primary prevention in patients at risk of sudden death., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results